Last reviewed 2026-04-20 · How we verify

Lipoclin (CLINOFIBRATE)

Phase 2 active Small molecule Quality 19/100

Lipoclin (generic name: CLINOFIBRATE) is a clinofibrate drug. It is currently in Phase 2 development.

Lipoclin works by influencing lipid metabolism, although the exact details of its mechanism are unclear.

Lipoclin (CLINOFIBRATE) is a small molecule clinofibrate drug with unknown target and commercial status. It is used to treat unknown indications, but its exact mechanism of action is not well-documented. As a clinofibrate, it is believed to work by modulating lipid metabolism, although specific details are lacking. Further research is needed to fully understand its effects and potential side effects. Its current owner and development status are also unclear.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CLINOFIBRATE
Drug class	clinofibrate
Modality	Small molecule
Therapeutic area	Metabolic
Phase	Phase 2

Mechanism of action

Think of Lipoclin like a key that helps unlock the body's natural processes for managing fats. It's believed to help the body use fats more efficiently, but the exact steps it takes to do this are not well understood. This can lead to improved cholesterol levels and overall heart health.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Lipoclin CI brief — competitive landscape report
Lipoclin updates RSS · CI watch RSS

Frequently asked questions about Lipoclin

What is Lipoclin?

Lipoclin (CLINOFIBRATE) is a clinofibrate drug.

How does Lipoclin work?

Lipoclin works by influencing lipid metabolism, although the exact details of its mechanism are unclear.

What is the generic name of Lipoclin?

CLINOFIBRATE is the generic (nonproprietary) name of Lipoclin.

What drug class is Lipoclin in?

Lipoclin belongs to the clinofibrate class. See all clinofibrate drugs at /class/clinofibrate.

What development phase is Lipoclin in?

Lipoclin is in Phase 2.

Drug class: All clinofibrate drugs
Therapeutic area: All drugs in Metabolic

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing